Results 141 to 150 of about 112,750 (306)
Movement Disorders, EarlyView.D2 receptor ablation in indirect‐pathway striatal neurons reduces or abolishes dyskinetic and dystonic behaviors induced by L‐DOPA or D2 receptor agonists, respectively. Contralateral turning is reduced, while forward locomotion is increased. These effects are associated with modulation of neuronal activity in dorsal striatum and external globus ...
Laura Andreoli +5 more
wiley +1 more source
POLG‐Related Parkinsonism with Good Response to Deep Brain Stimulation
Movement Disorders Clinical Practice, EarlyView.
Evdokia Efthymiou +4 more
wiley +1 more source
Movement Disorders, EarlyView.Abstract Deep brain stimulation (DBS) effectively treats motor symptoms in movement disorders but often compromises speech through incompletely defined mechanisms. We conducted a PROSPERO‐registered systematic review and meta‐analysis of publications through August 2024 (CRD42024527738).
Elina Tripoliti +15 more
wiley +1 more source
Levodopa Efficacy and GLP‐1 Receptor Agonists
Movement Disorders Clinical Practice, EarlyView.
Catherine Martinez +3 more
wiley +1 more source
Movement Disorders, EarlyView.ABSTRACT Background Dopa‐responsive dystonia is caused by pathogenic variants in the GCH1 gene. Although its clinical features and reduced penetrance are known, in vivo metabolic and structural alterations in symptomatic (sMC) and asymptomatic mutation carriers (aMC) remain poorly understood.
Jannik Prasuhn +12 more
wiley +1 more source
Phenotypic Clues in Infantile‐Onset Parkinsonism‐Dystonia‐2: A Treatable Neurotransmitter Disorder
Movement Disorders Clinical Practice, EarlyView.
Sangeetha Yoganathan +10 more
wiley +1 more source
Exercise, exerkines, and muscle–brain crosstalk in Parkinson's disease
Neuroprotection, EarlyView.Abstract Parkinson's disease (PD) is a progressive neurodegenerative disorder with motor and non‐motor symptoms, driven by dopaminergic loss and α‐synuclein accumulation. Beyond neurodegeneration, growing evidence highlights skeletal muscle health as a key determinant of prognosis, with sarcopenia and frailty contributing to greater disability, fall ...
Salomón Páez‐García +7 more
wiley +1 more source
Current Cell/Organoid and Animal Models for Primary Sclerosing Cholangitis
Portal Hypertension &Cirrhosis, EarlyView.Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with limited therapeutic options and a marked risk of progression to biliary fibrosis, cirrhosis, and malignancy. Progress in PSC research has been hindered by the lack of models that faithfully recapitulate the complex biliary microenvironment and disease heterogeneity ...
Qigu Yao +4 more
wiley +1 more source
Current Insight into Human Ornithine Aminotransferase: A Review
Proteins: Structure, Function, and Bioinformatics, EarlyView.ABSTRACT Human ornithine aminotransferase (hOAT) is a mitochondrial matrix pyridoxal‐5′‐phosphate enzyme (PLP) that catalyzes the reversible transfer of the δ‐amino group of L‐ornithine (L‐Orn) to α‐ketoglutarate (α‐KG) yielding glutamate‐5‐semialdehyde (GSA) and glutamate. GSA is prone to cyclize to Δ1‐pyrroline‐5‐carboxylate.
Fulvio Floriani +2 more
wiley +1 more source